

Breast Cancer Resection Pathology Reporting — pT Category (Primary Tumor) and pN Category (Regional Lymph Nodes) with Histologic Grade

Coding Specifications

Codes required to document patient has breast cancer and received a breast cancer resection surgical pathology examination:

A line item ICD-9-CM diagnosis code for breast cancer and a CPT code for breast cancer resection surgical pathology examination are required to identify patients to be included in this measure¹.

All measure-specific coding should be reported ON THE SAME CLAIM.

Breast cancer line item ICD-9-CM diagnosis codes

- 174.0, 174.1, 174.2, 174.3, 174.4, 174.5, 174.6, 174.8, 174.9 (malignant neoplasm of female breast)
- 175.0, 175.9 (malignant neoplasm of male breast)

AND

CPT codes

- 88307, 88309

Quality codes for this measure:

CPT II Code descriptors

(Data collection sheet should be used to determine appropriate code.)

- **CPT II 3250F:** Specimen site other than anatomic location of primary tumor
- **CPT II 3260F:** pT category (primary tumor), pN category (regional lymph nodes), and histologic grade documented in pathology report
- **CPT II 3260F-1P:** Documentation of medical reason(s) for not including pT category, pN category, and histologic grade in the pathology report (e.g., re-excision without residual tumor; non-carcinomas)
- **CPT II 3260F-8P:** pT category, pN category, and histologic grade were not documented in pathology report, reason not otherwise specified

¹Independent laboratories (ILs) and independent diagnostic testing facilities (IDTFs), using indicator Place of Service 81, are not included in PQRI.

Physician Performance Measures (Measures) and related data specifications, developed by the Physician Consortium for Performance Improvement® (the Consortium), are intended to facilitate quality improvement activities by physicians.

These Measures are intended to assist physicians in enhancing quality of care. Measures are designed for use by any physician who manages the care of a patient for a specific condition or for prevention. These performance Measures are not clinical guidelines and do not establish a standard of medical care. The Consortium has not tested its Measures for all potential applications. The Consortium encourages the testing and evaluation of its Measures. Measures are subject to review and may be revised or rescinded at any time by the Consortium. The Measures may not be altered without the prior written approval of the Consortium. Measures developed by the Consortium, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain. Commercial uses of the Measures require a license agreement between the user and American Medical Association, on behalf of the Consortium. Neither the Consortium nor its members shall be responsible for any use of these Measures.

THE MEASURES ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND

© 2007 American Medical Association and College of American Pathologists. All Rights Reserved.

Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The AMA, the Consortium and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications.

THE SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND.

CPT® contained in the Measures specifications is copyright 2007 American Medical Association.

PQRI 2010 Measure 99, Effective Date 01/01/2010
 © 2007 American Medical Association and College of American Pathologists. All Rights Reserved.
 CPT® copyright 2009 American Medical Association